These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 11274928)

  • 1. The expanding world of co-stimulation: the two-signal model revisited.
    Chambers CA
    Trends Immunol; 2001 Apr; 22(4):217-23. PubMed ID: 11274928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cells: A proliferation of costimulatory molecules.
    Mueller DL
    Curr Biol; 2000 Mar; 10(6):R227-30. PubMed ID: 10744968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costimulatory regulation of T cell function.
    Chambers CA; Allison JP
    Curr Opin Cell Biol; 1999 Apr; 11(2):203-10. PubMed ID: 10209159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the B7-CD28/CTLA-4 pathway in autoimmune disease.
    Chang TT; Kuchroo VK; Sharpe AH
    Curr Dir Autoimmun; 2002; 5():113-30. PubMed ID: 11826754
    [No Abstract]   [Full Text] [Related]  

  • 5. The ups and downs of T cell costimulation.
    Jenkins MK
    Immunity; 1994 Sep; 1(6):443-6. PubMed ID: 7534615
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting T cell costimulation in autoimmune disease.
    Stuart RW; Racke MK
    Expert Opin Ther Targets; 2002 Jun; 6(3):275-89. PubMed ID: 12223069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of costimulation to enhance tumor immunity.
    Vesosky B; Hurwitz AA
    Cancer Immunol Immunother; 2003 Nov; 52(11):663-9. PubMed ID: 12920481
    [No Abstract]   [Full Text] [Related]  

  • 8. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
    Carreno BM; Bennett F; Chau TA; Ling V; Luxenberg D; Jussif J; Baroja ML; Madrenas J
    J Immunol; 2000 Aug; 165(3):1352-6. PubMed ID: 10903737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of B7 signaling in the differentiation of naive CD4+ T cells to effector interleukin-4-producing T helper cells.
    Gause WC; Urban JF; Linsley P; Lu P
    Immunol Res; 1995; 14(3):176-88. PubMed ID: 8778208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interaction properties of costimulatory molecules revisited.
    Collins AV; Brodie DW; Gilbert RJ; Iaboni A; Manso-Sancho R; Walse B; Stuart DI; van der Merwe PA; Davis SJ
    Immunity; 2002 Aug; 17(2):201-10. PubMed ID: 12196291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.
    Vandenborre K; Van Gool SW; Kasran A; Ceuppens JL; Boogaerts MA; Vandenberghe P
    Immunology; 1999 Nov; 98(3):413-21. PubMed ID: 10583602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.
    Liu Z; Geboes K; Hellings P; Maerten P; Heremans H; Vandenberghe P; Boon L; van Kooten P; Rutgeerts P; Ceuppens JL
    J Immunol; 2001 Aug; 167(3):1830-8. PubMed ID: 11466409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance.
    Boussiotis VA; Gribben JG; Freeman GJ; Nadler LM
    Curr Opin Immunol; 1994 Oct; 6(5):797-807. PubMed ID: 7530013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative co-receptors on lymphocytes.
    Greenwald RJ; Latchman YE; Sharpe AH
    Curr Opin Immunol; 2002 Jun; 14(3):391-6. PubMed ID: 11973140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplantation and the CD28/CTLA4/B7 pathway.
    Alegre M; Fallarino F; Zhou P; Frauwirth K; Thistlethwaite J; Newell K; Gajewski T; Bluestone J
    Transplant Proc; 2001; 33(1-2):209-11. PubMed ID: 11266782
    [No Abstract]   [Full Text] [Related]  

  • 16. Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients.
    Pistillo MP; Tazzari PL; Bonifazi F; Bandini G; Kato T; Matsui T; Nishioka K; Conte R; Ferrara GB
    Transplantation; 2002 Apr; 73(8):1295-302. PubMed ID: 11981425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells.
    Lazetic S; Leong SR; Chang JC; Ong R; Dawes G; Punnonen J
    J Biol Chem; 2002 Oct; 277(41):38660-8. PubMed ID: 12167647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
    Mandelbrot DA; McAdam AJ; Sharpe AH
    J Exp Med; 1999 Jan; 189(2):435-40. PubMed ID: 9892625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New protein steals the show as 'costimulator' of T cells.
    Cohen J
    Science; 1993 Nov; 262(5135):844-5. PubMed ID: 7694360
    [No Abstract]   [Full Text] [Related]  

  • 20. CTLA-4 is required for the induction of high dose oral tolerance.
    Samoilova EB; Horton JL; Zhang H; Khoury SJ; Weiner HL; Chen Y
    Int Immunol; 1998 Apr; 10(4):491-8. PubMed ID: 9620605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.